[1] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014; 60, 2099−108. doi:  10.1002/hep.27406
[2] Chen H, Liu N, Ji ZH, et al. Assessment on the effects of hepatitis b prevention and control measures in western China: a Comparison of three population-based serosurveys. Biomed Environ Sci, 2020; 33, 735−44.
[3] Hadziyannis SJ. Milestones and perspectives in viral hepatitis B. Liver Int, 2011; 31 Suppl 1, 129-34.
[4] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017; 67, 370−98. doi:  10.1016/j.jhep.2017.03.021
[5] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018; 67, 358−80. doi:  10.1002/hep.29086
[6] Golsaz-Shirazi F, Amiri MM, Shokri F. Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection. Rev Med Virol, 2018; 28, e2007.
[7] Cao WH, Li MH, Pan CQ, et al. Quantitation of plasmacytoid dendritic cells in chronic hepatitis B patients with HBeAg positivity during PEG-IFN and entecavir therapy. J Interferon Cytokine Res, 2018; 38, 197−205. doi:  10.1089/jir.2018.0014
[8] Lei QS, Li TJ, Kong LN, et al. HBV-Pol is crucial for HBV-mediated inhibition of inflammasome activation and IL-1β production. Liver Int, 2019; 39, 2273−84. doi:  10.1111/liv.14214
[9] Kim DH, Park ES, Lee AR, et al. Intracellular interleukin-32γ mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun, 2018; 9, 3284. doi:  10.1038/s41467-018-05782-5
[10] Li MH, Chen QQ, Zhang L, et al. Association of cytokines with hepatitis B virus and its antigen. J Med Virol, 2020; 92, 3426−35. doi:  10.1002/jmv.26301
[11] Li MH, Zhang L, Zhang D, et al. Plasmacytoid dendritic cell function and cytokine network profiles in patients with acute or chronic hepatitis B virus infection. Chin Med J (Engl), 2018; 131, 43−9. doi:  10.4103/0366-6999.221275
[12] Li MH, Lu Y, Sun FF, et al. Transforming growth factor β as a possible independent factor in chronic hepatitis B. Arch Virol, 2021; 166, 1853−8. doi:  10.1007/s00705-021-05062-6
[13] Li MH, Lu HH, Chen QQ, et al. Changes in the cytokine profiles of patients with chronic hepatitis B during antiviral therapy. Biomed Environ Sci, 2021; 34, 443−53.
[14] Li MH, Zhang D, Zhang L, et al. Ratios of T-helper 2 cells to T-helper 1 cells and cytokine levels in patients with hepatitis B. Chin Med J (Engl), 2017; 130, 1810−5. doi:  10.4103/0366-6999.211541
[15] Waskow C, Liu K, Darrasse-Jèze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol, 2008; 9, 676−83. doi:  10.1038/ni.1615
[16] Guimond M, Freud AG, Mao HC, et al. In vivo role of Flt3 ligand and dendritic cells in NK Cell homeostasis. J Immunol, 2010; 184, 2769−75. doi:  10.4049/jimmunol.0900685
[17] Li MH, Lu Y, Zhang L, et al. Association of cytokines with alanine aminotransferase, hepatitis B virus surface antigen and hepatitis B envelope antigen levels in chronic hepatitis B. Chin Med J (Engl), 2018; 131, 1813−8. doi:  10.4103/0366-6999.237394
[18] European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015; 63, 237−64. doi:  10.1016/j.jhep.2015.04.006
[19] Li MH, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat, 2019; 26 Suppl 1, 32-41.
[20] Pan CQ, Li MH, Yi W, et al. Outcome of Chinese patients with Hepatitis B at 96 Weeks after functional cure With IFN versus combination regimens. Liver Int, 2021; 41, 1498−508. doi:  10.1111/liv.14801
[21] Li MH, Zhang L, Lu Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic Hepatitis B after treatment with pegylated interferonα-2a. Virol Sin, 2021; 36, 311−20. doi:  10.1007/s12250-020-00290-7
[22] Li MH, Zhang L, Qu XJ, et al. The predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis b during pegylated interferon alpha-2a treatment. Biomed Environ Sci, 2017; 30, 177−84.
[23] Rehermann B, Lau D, Hoofnagle JH, et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest, 1996; 97, 1655−65. doi:  10.1172/JCI118592
[24] Gong LL, Zhao BB, Fan WF, et al. Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians. Int J Clin Exp Pathol, 2015; 8, 8367−75.
[25] Chan HLY, Wong GLH, Chim AML, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther, 2011; 16, 1249−57. doi:  10.3851/IMP1921
[26] Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut, 2005; 54, 1604−9. doi:  10.1136/gut.2004.062208
[27] Odeh M, Sabo E, Srugo I, et al. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int, 2010; 24, 110−6.
[28] Cao WH, Li MH, Zhang L, et al. The characteristics of natural killer cells in chronic hepatitis B patients who received pegylated-interferon versus entecavir therapy. Biomed Res Int, 2021; 2021, 2178143.
[29] Belinskaia DA, Voronina PA, Shmurak VI, et al. Serum albumin in health and disease: esterase, antioxidant, transporting and signaling properties. Int J Mol Sci, 2021; 22, 10318. doi:  10.3390/ijms221910318